 |
|
|
| |
SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC)
|
| |
| |
Reported by Jules Levin
EASL 2013 April 26 Amsterdam
H Fontaine1, C Hezode2, C Dorival3, D Larrey4, F Zoulim5,V de Ledinghen6, V Canva7,
L Alric8, M Bourliere9, S Pol1, T Poynard10, G Riachi11, PH Bernard12, JJ Raabe13,
J Gournay14, S Metivier15, JM Pawlotsky16, D Samuel17, Y Barthe3, F Carrat3, JP Bronowicki18,
for the ANRS CO 20 CUPIC study group.
1.Hopital Cochin, Paris, 2. Hopital Henri Mondor, Creteil, 3. UMR-S 707, Paris, 4. Hopital Saint-Eloi, Montpellier, 5. INSERM U871, Lyon, France, 6.Hopital Haut Lêveque, Bordeaux, France 7. Hopital Clude Hurriez, Lille, France, 8. Medecine Interne, Hopital Purpan, Toulouse, 9. Fondation Saint-Joseph, Marseille, France, 10. Hepatologie, Hopital de la Pitie-Salpetriere, Paris, France 11. Hopital Charles Nicolle, Rouen, France, 12. Hoptal Saint-Andre, Bordeaux, France, 13. Hopital Bon Secours, Metz, France, 14. Hopital Universitaire de Nantes, Nantes, France 15. Hepatogastroenterologie, Hopital Purpan, Toulouse, France, 16. Hopital Henri Mondor, Creteil, France 17. Hopital Paul Brousse, Villejuif, France 17. Hopital de Brabois, Nancy, France
|
| |
|
|
|
|
|
